loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Tafamidis Meglumine reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Farmak Tafamidis Meglumine

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Tafamidis Meglumine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 18,074Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 5Vyndaqel/Vyndamax

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Vyndaqel/Vyndamax

    Tafamidis Meglumine

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Vyndaqel/Vyndamax

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Pfizer Inc.

    Tafamidis Meglumine

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2019 Revenue in Millions : 473

    2018 Revenue in Millions : 148

    Growth (%) : 220

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Vyndaqel/Vyndamax

    Tafamidis Meglumine

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Vyndaqel/Vyndamax

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Pfizer Inc.

    Tafamidis Meglumine

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 1,288

    2019 Revenue in Millions : 473

    Growth (%) : 172

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Vyndaqel/Vyndamax

    Tafamidis Meglumine

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Vyndaqel/Vyndamax

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Pfizer Inc.

    Tafamidis Meglumine

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 2,015

    2020 Revenue in Millions : 1,288

    Growth (%) : 56

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Vyndaqel/Vyndamax

    Tafamidis Meglumine

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Vyndaqel/Vyndamax

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Pfizer Inc.

    Tafamidis Meglumine

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2022 Revenue in Millions : 2,447

    2021 Revenue in Millions : 2,015

    Growth (%) : 21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Vyndaqel/Vyndamax

    Tafamidis Meglumine

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Vyndaqel/Vyndamax

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Pfizer Inc.

    Tafamidis Meglumine

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2023 Revenue in Millions : 3,321

    2022 Revenue in Millions : 2,447

    Growth (%) : 36

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF